SlideShare a Scribd company logo
1 of 24
Statin: The Good,
the Bad, and the
Unknown
DR. MOHAMMAD SAMIR AZAM SUNNY
DEPARTMENT OF CARDIAC SURGERY, BSMMU
What is statin?
 Statins (or HMG-CoA reductase inhibitors) are a
class of drugs used to lower cholesterol levels by
inhibiting the enzyme HMG-CoA reductase,
which plays a central role in the production of
cholesterol in the liver, which produces about 70
percent of total cholesterol in the body.
History
 In 1971, Akira Endo, a Japanese biochemist working for the pharmaceutical
company Sankyo, began the search for a cholesterol-lowering drug. Research
had already shown cholesterol is mostly manufactured by the body in the liver
using the enzyme.
 Joseph Goldstein, who won the Nobel Prize for related work on cholesterol, said
of Endo: "The millions of people whose lives will be extended through statin
therapy owe it all to Akira Endo.
The oyster mushroom,
naturally contains lovastatin.
Aspergillus terreus
Statins Classification
 Source
Natural: pravastatin, simvastatin, lovastatin
Synthetic: atorvastatin, fluvastatin
 Solubility
Lipophilic: simvastatin, atorvastatin, fluvastatin
Hydrophilic: pravastatin, rosuvastatin
Available forms
Statin Derivation
Atorvastatin Synthetic
Cerivastatin Synthetic
Fluvastatin Synthetic
Lovastatin Mushroom
Mevastatin
Pitavastatin
Yeast
Synthetic
Pravastatin bacteria
Rosuvastatin Synthetic
Simvastatin Aspergillus terreus
Simvastatin+Ezetimibe
Lovastatin+Niacin
Atorvastatin+Amlodipine
Simvastatin+Niacin
Cholesterol
 Cholesterol transported by lipoprotein.
 Low density lipoprotein: LDL transport cholesterol through out the
body
 High density lipoprotein: HDL removes excess cholesterol and carries
it back liver for degradation.
Who will be prescribed for Statin?
 Guidelines by the American College of Cardiology and the American
Heart Association recommend statin treatment for primary prevention
of cardiovascular disease in adults with LDL cholesterol > 190 mg/dL.
 On average, statins can lower LDL cholesterol by 1.8 mmol/l (70 mg/dl),
which translates into an estimated 60% decrease in the number of
cardiac events (heart attack, sudden cardiac death) and a 17%
reduced risk of stroke after long-term treatment. They have less effect
than the fibrates or niacin in reducing triglycerides and raising HDL-
cholesterol ("good cholesterol").
 In children - familial hypercholesterolemia.
 A recent meta-analysis of randomized controlled trials found that statins
could reduce the risk of contrast-induced nephropathy by 53% in
people undergoing coronary angiography/percutaneous interventions.
Statin therapy is generally a life long treatment. Discontinuation of statins is
followed within few weeks by a rise in LDL-C to pretreatment levels
Remember….
Dosages
The bad
 Cognitive Effects: statins and memory loss (including reports of
transient global amnesia), forgetfulness and confusion.
 Muscle pain: Coenzyme Q10 (ubiquinone) levels are decreased in
statin use. CoQ10 supplements are sometimes used to treat statin-
associated myopathy. Hydrophilic statins, such as fluvastatin,
rosuvastatin, and pravastatin, are less toxic than lipophilic statins,
such as atorvastatin, lovastatin, and simvastatin. Lowest with
pravastatin and fluvastatin, probably because they are more
hydrophilic and as a result have less muscle penetration.
 Diabetes
Initiation and Monitoring of Statin Therapy
 Evaluate muscle symptoms and CK before starting therapy
 Evaluate muscle symptoms 6 to 12 weeks after starting therapy and
at each follow-up visit
 If there is no CK elevation or if the CK value is < 3 times the upper
limit of normal, statin use can continue with careful monitoring
 Discontinuation of statin treatment is mandatory for CK elevations
>10 times the upper limit of normal
Drug interactions
 Combining any statin with a fibrate or niacin, another category of
lipid-lowering drugs, increases the risks for rhabdomyolysis to almost
6.0 per 10,000 person-years(Graham et all "Incidence of hospitalized
rhabdomyolysis in patients treated with lipid-lowering drugs". JAMA
292 (21): 2585–90)
 Warfarin: Atorvastatin has not been reported to interact with
warfarin. warfarin-simvastatin interaction repoted( Ann
Pharmacother. 2007 Jul;41(7):1292-5)
 Consumption of grapefruit or grapefruit juice (Mayo clinic: article on
interference between grapefruit and medication)
ACCF/AHA Guideline for Coronary
Artery Bypass Graft Surgery
 Management of Hyperlipidemia: Recommendations
Class I
 1All patients undergoing CABG should receive statin therapy, unless contraindicated (Level of Evidence:
A)
 2In patients undergoing CABG, an adequate dose of statin should be used to reduce LDL cholesterol to
less than 100 mg/dL and to achieve at least a 30% lowering of LDL cholesterol . (Level of Evidence: C)
Class IIa
 1In patients undergoing CABG, it is reasonable to treat with statin therapy to lower the LDL cholesterol to
less than 70 mg/dL in very high-risk⁎
 ⁎ ⁎Presence of established cardiovascular disease plus 1) multiple major risk factors (especially diabetes),
2) severe and poorly controlled risk factors (especially continued cigarette smoking), 3) multiple risk
factors of the metabolic syndrome (especially high triglycerides ≥200 mg/dL plus non–high-density
lipoprotein cholesterol ≥130 mg/dL with low high-density lipoprotein cholesterol [<40 mg/dL]), and 4)
acute coronary syndromes.
patients undergoing urgent or emergency CABG who are not taking a statin, it is reasonable to initiate
high-dose
statin therapy immediately (564). (Level of Evidence: C)
Class III: Harm
 Discontinuation of statin or other dyslipidemic therapy is not recommended before or after CABG in
patients without adverse reactions to therapy . (Level of Evidence: B)
Which is the Best statin for the postoperative coronary artery
bypass graft patient?
 Statin Therapy Prior to CABG Surgery May Improve Outcomes
(circulation 2008)
 Statin therapy initiated in the early months after hospital discharge
independently reduces all-cause mortality and major adverse
cardiovascular events after CABG(socity of thoracic surgeon 2012)
 Rosuvastatin’s superiority over other statins in allowing patients to
reach LDL-C targets has been maintained in ‘real-world’
observational studies. Rosuvastatin has also been shown to increase
high-density lipid cholesterol (HDL-C) by greater proportions in
comparison with other statins, providing increased anti-atherogenic
effects. (oxford journal vol 36)
Statin: Role over RSVG
 Statin therapy to achieve LDL levels less than 100 mg/dL was
independently associated with improved graft patency in the
CASCADE trial( Ann Thorac Surg. 2011 Oct;92(4):1284-90)
 Statin therapy is associated with improved graft patency after
infrainguinal bypass grafting with saphenous vein(J Vasc Surg. 2004
Jun;39(6):1178-85)
 Use of statin causes Patency of Vein Grafts in the Modern Era (RAPS
study Canada) SVG patency 80% @7yrs(J Am Coll Cardiol
2012:60;28-35)
 Effect of STATINS , LDL 1yr results Patency of Vein Grafts in the
Modern Era LDL<100mg/dl SVG patency 96% ; Less intimal
hyperplasia when LDL<100mg/dl(kullic et al Ann Thorac Surg
2011:92;1284)
The ultimate
 Venous graft patency increases almost double if
20 mg atorvastatin / 10 mg Rusovastatin
continuously taken after CABG maintaining LDL
level <100mg/dl. (Canadian society of
cardiology, over 1000 patient, 2014)
In pipeline
 New cholesterol lowering drugs being developed
 Gladridin- found in the root of licorice and anise plant
 Appears to inhibit oxidation of LDL cholesterol, which is a factor in
the build up of arterial plaque.
THANK YOU

More Related Content

What's hot

What's hot (20)

Antihypertensive drugs
Antihypertensive drugsAntihypertensive drugs
Antihypertensive drugs
 
Antihypertensive drugs
Antihypertensive drugsAntihypertensive drugs
Antihypertensive drugs
 
ACE Inhibitors
ACE InhibitorsACE Inhibitors
ACE Inhibitors
 
Proton pump inhibitor
Proton pump inhibitorProton pump inhibitor
Proton pump inhibitor
 
Anticoagulants
AnticoagulantsAnticoagulants
Anticoagulants
 
Oral hypoglycemics
Oral hypoglycemicsOral hypoglycemics
Oral hypoglycemics
 
Pharmacological management of heart failure
Pharmacological management of heart failurePharmacological management of heart failure
Pharmacological management of heart failure
 
Diuretics...
Diuretics...Diuretics...
Diuretics...
 
Pharmacology of Anti platelet drugs
Pharmacology of Anti platelet drugsPharmacology of Anti platelet drugs
Pharmacology of Anti platelet drugs
 
Metformin A Pharmacological Preespective
Metformin A Pharmacological PreespectiveMetformin A Pharmacological Preespective
Metformin A Pharmacological Preespective
 
Antiarrhythmic drugs
Antiarrhythmic drugsAntiarrhythmic drugs
Antiarrhythmic drugs
 
Statins
StatinsStatins
Statins
 
Drugs affecting renin-angiotensin system
Drugs affecting renin-angiotensin systemDrugs affecting renin-angiotensin system
Drugs affecting renin-angiotensin system
 
Pharmacotherapy of dyslipidemia
Pharmacotherapy of dyslipidemiaPharmacotherapy of dyslipidemia
Pharmacotherapy of dyslipidemia
 
Anticoagulants
AnticoagulantsAnticoagulants
Anticoagulants
 
Calcium channel blockers nikku
Calcium channel blockers nikkuCalcium channel blockers nikku
Calcium channel blockers nikku
 
Cardiovascular Drugs
Cardiovascular DrugsCardiovascular Drugs
Cardiovascular Drugs
 
Antidiabetic drugs
Antidiabetic drugsAntidiabetic drugs
Antidiabetic drugs
 
Antihyperlipidemic drugs
Antihyperlipidemic drugsAntihyperlipidemic drugs
Antihyperlipidemic drugs
 
Antiarrhythmic drugs bds
Antiarrhythmic drugs bdsAntiarrhythmic drugs bds
Antiarrhythmic drugs bds
 

Similar to Statin

Hope 3 trial acc 2016 (4) (1)
Hope 3 trial acc 2016 (4) (1)Hope 3 trial acc 2016 (4) (1)
Hope 3 trial acc 2016 (4) (1)Hirdesh Chawla
 
2013 ACC/AHA guidelines for blood cholesterol management
2013 ACC/AHA guidelines for blood cholesterol management2013 ACC/AHA guidelines for blood cholesterol management
2013 ACC/AHA guidelines for blood cholesterol managementPraveen Nagula
 
how low to go with LDL
how low to go with LDL how low to go with LDL
how low to go with LDL Praveen Nagula
 
Hypolipidaemic Drugs
Hypolipidaemic DrugsHypolipidaemic Drugs
Hypolipidaemic DrugsDinesh Kumar
 
Rafael Carmena Rodriguéz en Clinicardio09: Novedades en práctica clínica sobr...
Rafael Carmena Rodriguéz en Clinicardio09: Novedades en práctica clínica sobr...Rafael Carmena Rodriguéz en Clinicardio09: Novedades en práctica clínica sobr...
Rafael Carmena Rodriguéz en Clinicardio09: Novedades en práctica clínica sobr...Sociedad Española de Cardiología
 
PHARMACOTHERAPY POINTERS FOR ATHEROSCLEROSIS [MALAYSIAN CPGs].pdf
PHARMACOTHERAPY POINTERS FOR ATHEROSCLEROSIS [MALAYSIAN CPGs].pdfPHARMACOTHERAPY POINTERS FOR ATHEROSCLEROSIS [MALAYSIAN CPGs].pdf
PHARMACOTHERAPY POINTERS FOR ATHEROSCLEROSIS [MALAYSIAN CPGs].pdfsamthamby79
 
Guidelines for prevention of stroke Guidelines for prevention of stroke
Guidelines for prevention of stroke 	 Guidelines for prevention of strokeGuidelines for prevention of stroke 	 Guidelines for prevention of stroke
Guidelines for prevention of stroke Guidelines for prevention of strokeMedicineAndHealthNeurolog
 
HMG-CoA reductase inhibitors.pptx
HMG-CoA reductase inhibitors.pptxHMG-CoA reductase inhibitors.pptx
HMG-CoA reductase inhibitors.pptxDr. Manoj Kumbhare
 
Dyslipidemia management an evidence based approach
Dyslipidemia management an evidence based approachDyslipidemia management an evidence based approach
Dyslipidemia management an evidence based approachDr Vivek Baliga
 
Cardio updates 2019 power point template
Cardio updates 2019 power point templateCardio updates 2019 power point template
Cardio updates 2019 power point templateHaytham Ghareeb
 
aswin stroke presentation.pptx
aswin stroke presentation.pptxaswin stroke presentation.pptx
aswin stroke presentation.pptxhadisadiq
 
aswinstrokepresentation-230906150057-f666ca76.pdf
aswinstrokepresentation-230906150057-f666ca76.pdfaswinstrokepresentation-230906150057-f666ca76.pdf
aswinstrokepresentation-230906150057-f666ca76.pdfAndiMuhammadSyukur
 
Drugs and the kidney
Drugs and the kidneyDrugs and the kidney
Drugs and the kidneyraj kumar
 

Similar to Statin (20)

dyslipidemia
dyslipidemiadyslipidemia
dyslipidemia
 
Lipid lowering after an Acute Coronary Syndrome -strategies for success
Lipid lowering after an Acute Coronary Syndrome -strategies for successLipid lowering after an Acute Coronary Syndrome -strategies for success
Lipid lowering after an Acute Coronary Syndrome -strategies for success
 
Hypolipidemic drugs
Hypolipidemic drugsHypolipidemic drugs
Hypolipidemic drugs
 
Hope 3 trial acc 2016 (4) (1)
Hope 3 trial acc 2016 (4) (1)Hope 3 trial acc 2016 (4) (1)
Hope 3 trial acc 2016 (4) (1)
 
2013 ACC/AHA guidelines for blood cholesterol management
2013 ACC/AHA guidelines for blood cholesterol management2013 ACC/AHA guidelines for blood cholesterol management
2013 ACC/AHA guidelines for blood cholesterol management
 
how low to go with LDL
how low to go with LDL how low to go with LDL
how low to go with LDL
 
Antihiperlipidemia varga 2021
Antihiperlipidemia varga 2021Antihiperlipidemia varga 2021
Antihiperlipidemia varga 2021
 
Hypolipidaemic Drugs
Hypolipidaemic DrugsHypolipidaemic Drugs
Hypolipidaemic Drugs
 
Rafael Carmena Rodriguéz en Clinicardio09: Novedades en práctica clínica sobr...
Rafael Carmena Rodriguéz en Clinicardio09: Novedades en práctica clínica sobr...Rafael Carmena Rodriguéz en Clinicardio09: Novedades en práctica clínica sobr...
Rafael Carmena Rodriguéz en Clinicardio09: Novedades en práctica clínica sobr...
 
Dyslipidemia 2016
Dyslipidemia 2016Dyslipidemia 2016
Dyslipidemia 2016
 
Rosuvastatin
RosuvastatinRosuvastatin
Rosuvastatin
 
PHARMACOTHERAPY POINTERS FOR ATHEROSCLEROSIS [MALAYSIAN CPGs].pdf
PHARMACOTHERAPY POINTERS FOR ATHEROSCLEROSIS [MALAYSIAN CPGs].pdfPHARMACOTHERAPY POINTERS FOR ATHEROSCLEROSIS [MALAYSIAN CPGs].pdf
PHARMACOTHERAPY POINTERS FOR ATHEROSCLEROSIS [MALAYSIAN CPGs].pdf
 
Guidelines for prevention of stroke Guidelines for prevention of stroke
Guidelines for prevention of stroke 	 Guidelines for prevention of strokeGuidelines for prevention of stroke 	 Guidelines for prevention of stroke
Guidelines for prevention of stroke Guidelines for prevention of stroke
 
HMG-CoA reductase inhibitors.pptx
HMG-CoA reductase inhibitors.pptxHMG-CoA reductase inhibitors.pptx
HMG-CoA reductase inhibitors.pptx
 
Dyslipidemia management an evidence based approach
Dyslipidemia management an evidence based approachDyslipidemia management an evidence based approach
Dyslipidemia management an evidence based approach
 
Cardio updates 2019 power point template
Cardio updates 2019 power point templateCardio updates 2019 power point template
Cardio updates 2019 power point template
 
aswin stroke presentation.pptx
aswin stroke presentation.pptxaswin stroke presentation.pptx
aswin stroke presentation.pptx
 
aswinstrokepresentation-230906150057-f666ca76.pdf
aswinstrokepresentation-230906150057-f666ca76.pdfaswinstrokepresentation-230906150057-f666ca76.pdf
aswinstrokepresentation-230906150057-f666ca76.pdf
 
Pragmatic Use of Rosuvastatin for CVD Prevention
Pragmatic Use of Rosuvastatin for CVD PreventionPragmatic Use of Rosuvastatin for CVD Prevention
Pragmatic Use of Rosuvastatin for CVD Prevention
 
Drugs and the kidney
Drugs and the kidneyDrugs and the kidney
Drugs and the kidney
 

Recently uploaded

Measurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxMeasurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxDr. Dheeraj Kumar
 
See the 2,456 pharmacies on the National E-Pharmacy Platform
See the 2,456 pharmacies on the National E-Pharmacy PlatformSee the 2,456 pharmacies on the National E-Pharmacy Platform
See the 2,456 pharmacies on the National E-Pharmacy PlatformKweku Zurek
 
History and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfHistory and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfSasikiranMarri
 
Primary headache and facial pain. (2024)
Primary headache and facial pain. (2024)Primary headache and facial pain. (2024)
Primary headache and facial pain. (2024)Mohamed Rizk Khodair
 
Pharmaceutical Marketting: Unit-5, Pricing
Pharmaceutical Marketting: Unit-5, PricingPharmaceutical Marketting: Unit-5, Pricing
Pharmaceutical Marketting: Unit-5, PricingArunagarwal328757
 
Biomechanics- Shoulder Joint!!!!!!!!!!!!
Biomechanics- Shoulder Joint!!!!!!!!!!!!Biomechanics- Shoulder Joint!!!!!!!!!!!!
Biomechanics- Shoulder Joint!!!!!!!!!!!!ibtesaam huma
 
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaurMETHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaurNavdeep Kaur
 
Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.Prerana Jadhav
 
LUNG TUMORS AND ITS CLASSIFICATIONS.pdf
LUNG TUMORS AND ITS  CLASSIFICATIONS.pdfLUNG TUMORS AND ITS  CLASSIFICATIONS.pdf
LUNG TUMORS AND ITS CLASSIFICATIONS.pdfDolisha Warbi
 
Glomerular Filtration rate and its determinants.pptx
Glomerular Filtration rate and its determinants.pptxGlomerular Filtration rate and its determinants.pptx
Glomerular Filtration rate and its determinants.pptxDr.Nusrat Tariq
 
Apiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptApiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptkedirjemalharun
 
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara RajendranMusic Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara RajendranTara Rajendran
 
POST NATAL EXERCISES AND ITS IMPACT.pptx
POST NATAL EXERCISES AND ITS IMPACT.pptxPOST NATAL EXERCISES AND ITS IMPACT.pptx
POST NATAL EXERCISES AND ITS IMPACT.pptxvirengeeta
 
Presentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPresentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPrerana Jadhav
 
call girls in munirka DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in munirka  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️call girls in munirka  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in munirka DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️saminamagar
 
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
COVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptxCOVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptx
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptxBibekananda shah
 
call girls in paharganj DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in paharganj DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️call girls in paharganj DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in paharganj DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️saminamagar
 
PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
PNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdfPNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdf
PNEUMOTHORAX AND ITS MANAGEMENTS.pdfDolisha Warbi
 
Radiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptxRadiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptxDr. Dheeraj Kumar
 
call girls in Dwarka Sector 21 Metro DELHI 🔝 >༒9540349809 🔝 genuine Escort Se...
call girls in Dwarka Sector 21 Metro DELHI 🔝 >༒9540349809 🔝 genuine Escort Se...call girls in Dwarka Sector 21 Metro DELHI 🔝 >༒9540349809 🔝 genuine Escort Se...
call girls in Dwarka Sector 21 Metro DELHI 🔝 >༒9540349809 🔝 genuine Escort Se...saminamagar
 

Recently uploaded (20)

Measurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxMeasurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptx
 
See the 2,456 pharmacies on the National E-Pharmacy Platform
See the 2,456 pharmacies on the National E-Pharmacy PlatformSee the 2,456 pharmacies on the National E-Pharmacy Platform
See the 2,456 pharmacies on the National E-Pharmacy Platform
 
History and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfHistory and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdf
 
Primary headache and facial pain. (2024)
Primary headache and facial pain. (2024)Primary headache and facial pain. (2024)
Primary headache and facial pain. (2024)
 
Pharmaceutical Marketting: Unit-5, Pricing
Pharmaceutical Marketting: Unit-5, PricingPharmaceutical Marketting: Unit-5, Pricing
Pharmaceutical Marketting: Unit-5, Pricing
 
Biomechanics- Shoulder Joint!!!!!!!!!!!!
Biomechanics- Shoulder Joint!!!!!!!!!!!!Biomechanics- Shoulder Joint!!!!!!!!!!!!
Biomechanics- Shoulder Joint!!!!!!!!!!!!
 
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaurMETHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
 
Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.
 
LUNG TUMORS AND ITS CLASSIFICATIONS.pdf
LUNG TUMORS AND ITS  CLASSIFICATIONS.pdfLUNG TUMORS AND ITS  CLASSIFICATIONS.pdf
LUNG TUMORS AND ITS CLASSIFICATIONS.pdf
 
Glomerular Filtration rate and its determinants.pptx
Glomerular Filtration rate and its determinants.pptxGlomerular Filtration rate and its determinants.pptx
Glomerular Filtration rate and its determinants.pptx
 
Apiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptApiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.ppt
 
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara RajendranMusic Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
 
POST NATAL EXERCISES AND ITS IMPACT.pptx
POST NATAL EXERCISES AND ITS IMPACT.pptxPOST NATAL EXERCISES AND ITS IMPACT.pptx
POST NATAL EXERCISES AND ITS IMPACT.pptx
 
Presentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPresentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous System
 
call girls in munirka DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in munirka  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️call girls in munirka  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in munirka DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
 
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
COVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptxCOVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptx
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
 
call girls in paharganj DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in paharganj DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️call girls in paharganj DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in paharganj DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
 
PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
PNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdfPNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdf
PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
 
Radiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptxRadiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptx
 
call girls in Dwarka Sector 21 Metro DELHI 🔝 >༒9540349809 🔝 genuine Escort Se...
call girls in Dwarka Sector 21 Metro DELHI 🔝 >༒9540349809 🔝 genuine Escort Se...call girls in Dwarka Sector 21 Metro DELHI 🔝 >༒9540349809 🔝 genuine Escort Se...
call girls in Dwarka Sector 21 Metro DELHI 🔝 >༒9540349809 🔝 genuine Escort Se...
 

Statin

  • 1. Statin: The Good, the Bad, and the Unknown DR. MOHAMMAD SAMIR AZAM SUNNY DEPARTMENT OF CARDIAC SURGERY, BSMMU
  • 2. What is statin?  Statins (or HMG-CoA reductase inhibitors) are a class of drugs used to lower cholesterol levels by inhibiting the enzyme HMG-CoA reductase, which plays a central role in the production of cholesterol in the liver, which produces about 70 percent of total cholesterol in the body.
  • 3. History  In 1971, Akira Endo, a Japanese biochemist working for the pharmaceutical company Sankyo, began the search for a cholesterol-lowering drug. Research had already shown cholesterol is mostly manufactured by the body in the liver using the enzyme.  Joseph Goldstein, who won the Nobel Prize for related work on cholesterol, said of Endo: "The millions of people whose lives will be extended through statin therapy owe it all to Akira Endo. The oyster mushroom, naturally contains lovastatin. Aspergillus terreus
  • 4. Statins Classification  Source Natural: pravastatin, simvastatin, lovastatin Synthetic: atorvastatin, fluvastatin  Solubility Lipophilic: simvastatin, atorvastatin, fluvastatin Hydrophilic: pravastatin, rosuvastatin
  • 5. Available forms Statin Derivation Atorvastatin Synthetic Cerivastatin Synthetic Fluvastatin Synthetic Lovastatin Mushroom Mevastatin Pitavastatin Yeast Synthetic Pravastatin bacteria Rosuvastatin Synthetic Simvastatin Aspergillus terreus Simvastatin+Ezetimibe Lovastatin+Niacin Atorvastatin+Amlodipine Simvastatin+Niacin
  • 6. Cholesterol  Cholesterol transported by lipoprotein.  Low density lipoprotein: LDL transport cholesterol through out the body  High density lipoprotein: HDL removes excess cholesterol and carries it back liver for degradation.
  • 7.
  • 8.
  • 9.
  • 10. Who will be prescribed for Statin?  Guidelines by the American College of Cardiology and the American Heart Association recommend statin treatment for primary prevention of cardiovascular disease in adults with LDL cholesterol > 190 mg/dL.  On average, statins can lower LDL cholesterol by 1.8 mmol/l (70 mg/dl), which translates into an estimated 60% decrease in the number of cardiac events (heart attack, sudden cardiac death) and a 17% reduced risk of stroke after long-term treatment. They have less effect than the fibrates or niacin in reducing triglycerides and raising HDL- cholesterol ("good cholesterol").  In children - familial hypercholesterolemia.  A recent meta-analysis of randomized controlled trials found that statins could reduce the risk of contrast-induced nephropathy by 53% in people undergoing coronary angiography/percutaneous interventions.
  • 11.
  • 12. Statin therapy is generally a life long treatment. Discontinuation of statins is followed within few weeks by a rise in LDL-C to pretreatment levels Remember….
  • 14. The bad  Cognitive Effects: statins and memory loss (including reports of transient global amnesia), forgetfulness and confusion.  Muscle pain: Coenzyme Q10 (ubiquinone) levels are decreased in statin use. CoQ10 supplements are sometimes used to treat statin- associated myopathy. Hydrophilic statins, such as fluvastatin, rosuvastatin, and pravastatin, are less toxic than lipophilic statins, such as atorvastatin, lovastatin, and simvastatin. Lowest with pravastatin and fluvastatin, probably because they are more hydrophilic and as a result have less muscle penetration.  Diabetes
  • 15.
  • 16.
  • 17. Initiation and Monitoring of Statin Therapy  Evaluate muscle symptoms and CK before starting therapy  Evaluate muscle symptoms 6 to 12 weeks after starting therapy and at each follow-up visit  If there is no CK elevation or if the CK value is < 3 times the upper limit of normal, statin use can continue with careful monitoring  Discontinuation of statin treatment is mandatory for CK elevations >10 times the upper limit of normal
  • 18. Drug interactions  Combining any statin with a fibrate or niacin, another category of lipid-lowering drugs, increases the risks for rhabdomyolysis to almost 6.0 per 10,000 person-years(Graham et all "Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs". JAMA 292 (21): 2585–90)  Warfarin: Atorvastatin has not been reported to interact with warfarin. warfarin-simvastatin interaction repoted( Ann Pharmacother. 2007 Jul;41(7):1292-5)  Consumption of grapefruit or grapefruit juice (Mayo clinic: article on interference between grapefruit and medication)
  • 19. ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery  Management of Hyperlipidemia: Recommendations Class I  1All patients undergoing CABG should receive statin therapy, unless contraindicated (Level of Evidence: A)  2In patients undergoing CABG, an adequate dose of statin should be used to reduce LDL cholesterol to less than 100 mg/dL and to achieve at least a 30% lowering of LDL cholesterol . (Level of Evidence: C) Class IIa  1In patients undergoing CABG, it is reasonable to treat with statin therapy to lower the LDL cholesterol to less than 70 mg/dL in very high-risk⁎  ⁎ ⁎Presence of established cardiovascular disease plus 1) multiple major risk factors (especially diabetes), 2) severe and poorly controlled risk factors (especially continued cigarette smoking), 3) multiple risk factors of the metabolic syndrome (especially high triglycerides ≥200 mg/dL plus non–high-density lipoprotein cholesterol ≥130 mg/dL with low high-density lipoprotein cholesterol [<40 mg/dL]), and 4) acute coronary syndromes. patients undergoing urgent or emergency CABG who are not taking a statin, it is reasonable to initiate high-dose statin therapy immediately (564). (Level of Evidence: C) Class III: Harm  Discontinuation of statin or other dyslipidemic therapy is not recommended before or after CABG in patients without adverse reactions to therapy . (Level of Evidence: B)
  • 20. Which is the Best statin for the postoperative coronary artery bypass graft patient?  Statin Therapy Prior to CABG Surgery May Improve Outcomes (circulation 2008)  Statin therapy initiated in the early months after hospital discharge independently reduces all-cause mortality and major adverse cardiovascular events after CABG(socity of thoracic surgeon 2012)  Rosuvastatin’s superiority over other statins in allowing patients to reach LDL-C targets has been maintained in ‘real-world’ observational studies. Rosuvastatin has also been shown to increase high-density lipid cholesterol (HDL-C) by greater proportions in comparison with other statins, providing increased anti-atherogenic effects. (oxford journal vol 36)
  • 21. Statin: Role over RSVG  Statin therapy to achieve LDL levels less than 100 mg/dL was independently associated with improved graft patency in the CASCADE trial( Ann Thorac Surg. 2011 Oct;92(4):1284-90)  Statin therapy is associated with improved graft patency after infrainguinal bypass grafting with saphenous vein(J Vasc Surg. 2004 Jun;39(6):1178-85)  Use of statin causes Patency of Vein Grafts in the Modern Era (RAPS study Canada) SVG patency 80% @7yrs(J Am Coll Cardiol 2012:60;28-35)  Effect of STATINS , LDL 1yr results Patency of Vein Grafts in the Modern Era LDL<100mg/dl SVG patency 96% ; Less intimal hyperplasia when LDL<100mg/dl(kullic et al Ann Thorac Surg 2011:92;1284)
  • 22. The ultimate  Venous graft patency increases almost double if 20 mg atorvastatin / 10 mg Rusovastatin continuously taken after CABG maintaining LDL level <100mg/dl. (Canadian society of cardiology, over 1000 patient, 2014)
  • 23. In pipeline  New cholesterol lowering drugs being developed  Gladridin- found in the root of licorice and anise plant  Appears to inhibit oxidation of LDL cholesterol, which is a factor in the build up of arterial plaque.